However, we found that patients who have undergone endocrine therapy, a chemopreventive measure targeting the estrogen receptor which promotes proliferation in BC cells, are significantly more likely to survive if they have relatively low level of CHD2 expression than those who have a high level of CHD2 (Fig. 3D). The gene discussed is CHD2; the disease is breast cancer.